The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
64
Mayo Clinic - Arizona
Scottsdale, Arizona, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Maximum tolerated dose
Dose limiting toxicity
Safety profile
Evaluation of pharmacokinetics and pharmacodynamics
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mayo Clinic - Minnesota
Rochester, Minnesota, United States